There are 169 resources available
Q&A and discussion
Presenter: All Speakers
Session: What data I need from the lab before running a phase I
Resources:
Webcast
Armoured effector cells for treatment of solid tumors
Presenter: Michael O’Dwyer
Session: Adoptive cell therapies in solid tumours
Resources:
Slides
Webcast
Resistance to CART therapy
Presenter: Patrizia Porazzi
Session: Adoptive cell therapies in solid tumours
Resources:
Slides
Webcast
Tumor agnostic development of antibody-drug conjugates
Presenter: Barbara Pistilli
Session: What’s new on antibody-drug conjugates?
Resources:
Slides
Webcast
Optimising the safety of novel antibody-drug conjugates
Presenter: Toshio Shimizu
Session: What’s new on antibody-drug conjugates?
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: What’s new on antibody-drug conjugates?
Resources:
Webcast
Delivering excellence in early clinical trials
Presenter: Christina Yap
Session: Multidisciplinary trials
Resources:
Slides
Webcast
Ensuring early clinical trial reporting
Presenter: Neeltje Steeghs
Session: Multidisciplinary trials
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Multidisciplinary trials
Resources:
Webcast
85O - Low-pass whole genome sequencing (lpWGS) to quantify circulating tumor DNA (ctDNA) burden as a pharmacodynamic response biomarker in patients on early phase trials
Presenter: Aaron Tan
Session: Abstract session 2
Resources:
Abstract
Slides
Webcast